How effective is safinamide (Xadago) in in increasing the benefit of levodopa in the management of Parkinson disease (PD)?

Updated: Aug 29, 2019
  • Author: Robert A Hauser, MD, MBA; Chief Editor: Selim R Benbadis, MD  more...
  • Print

Safinamide (Xadago), a MAO-B inhibitor, was approved by the FDA in March 2017 as add-on treatment for patients with Parkinson disease who are currently taking levodopa/carbidopa and experiencing “off” episodes. It is the first new chemical entity approved in the United States in more than 10 years. Approval was based on 2 phase-III trials that included nearly 1200 patients who had PD with motor fluctuations. Results showed that safinamide as add-on treatment to levodopa/carbidopa provided a significant reduction in off-time and a significant increase in on-time without troublesome dyskinesia in patients experiencing motor fluctuations. [56, 57]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!